Organogenesis Q1 revenue down 4% to $98.1M; net income drops to $0.1M from $9.9M

Organogenesis Holdings Inc.

2022-Q1 EPS reported $0.00 revenue$98,117,000

Net revenue $98.1M, down 4% YoY; adjusted net income $1.2M vs $11.2M.
Surgical & Sports Medicine revenue fell 39% to $7.2M due to ReNu/NuCel discontinuation.
PuraPly revenue grew 29% to $53.3M, partially offsetting declines.
Adjusted EBITDA $5.0M, down 69% from $16.0M; cash at $108.5M.
FY2022 guidance: net revenue $485M-$515M, net income $41.2M-$52.7M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.